Trial · NCT04414618
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measurement of the Change in Oxygen Requirement From Baseline | 14 days | Maximal oxygen flow (L/min) was recorded daily for the 14 days of treatment for each participant. Participant individual area under the curve (AUC) was calculated based on the trapezoidal rule, after subtracting the baseline oxygen requirement at each day. The median AUC absolute change from baseline (L/min) for each treatment arm is presented. |
| Secondary | Measurement of Time to the Reduction in Oxygen Requirement. | 14 days | The time required between arms to achieve 50% reduction from baseline in supplemental oxygen based on oxygen flow in L/min. |
| Secondary | The Percentage of Subjects no Longer Receiving Supplemental Oxygen for at Least 24 Hours by Day 14 | 14 days | The percentage of subjects in each arm no longer requiring supplemental oxygen for at least 24 hours by Day 14. |
| Secondary | Time to Negative Swabs for SARS-CoV-2 by PCR Post Treatment | 6 weeks | The time in each arm to two consecutive negative swabs for SARS-CoV-2 by PCR nasopharyngeal or oropharyngeal swab, at least 24 hrs. apart. |
| Secondary | The Percentage of Subjects With at Least Two Consecutive Negative Swabs for SARS-CoV-2 by PCR at Day 14 | 14 days | The percentage of subjects in each arm to achieve two consecutive negative PCR nasopharyngeal or oropharyngeal swabs for SARS-CoV-2 at Day 14, at least 24 hrs. apart. |
| Secondary | Intubation and Mechanical Ventilation Requirements | From screening phase and every day from day 1 to day 14 of treatment | The percentage of patients in each arm who require intubation and mechanical ventilation by Day 14 |
| Secondary | Evaluation of the Time to Intubation and Mechanical Ventilation | From screening phase and every day from day 1 to day 14 of treatment | The time in each arm for the patient to require mechanical ventilation. |
| Secondary | Evaluation the Proportion of Patients, With at Least One Measurement of Fever at Baseline Who Are Afebrile at Day 14 | From screening phase and every day from day 1 to day 14 of treatment | The proportion of patients in each arm, with at least one measurement of fever at baseline (defined as temperature \>38.0 C\[100.4 F\]), who are afebrile (defined as temperature \<37.2C \[99 F\]) at Day 14 |
| Secondary | Evaluation of Mortality 30 Days Post-baseline | 30 days after day 1 of treatment | The mortality in each arm 30 days post-baseline. |
| Other | Safety TEAEs | 6 weeks | The number of subjects with treatment-emergent adverse events in each arm of all treatment-emergent adverse events (TEAEs). |
| Other | Safety SAEs | 6 weeks | The number of subjects with serious adverse events (SAEs) in each arm. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04414618/registered